All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

When would you switch a patient with myelofibrosis from ruxolitinib?

During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Haifa Kathrin Al-Ali, University Hospital Halle (Saale), Halle, DE. We asked, When would you switch a patient with myelofibrosis from ruxolitinib?

When would you switch a patient with myelofibrosis from ruxolitinib?

To answer this question, Al-Ali suggests decisions on switching from ruxolitinib should be made on an individual basis and by considering the overall clinical picture of patients with relapsed/refractory or ruxolitinib-intolerant disease.

Share: